Investing in the science that defines tomorrow’s medicine

Luma Group is a multistage investment firm focused on biotechnology, bringing together scientific insight and computation to shape both our investment strategy and the companies we back.

Explore Portfolio

First-principles science

We partner with teams that have deep biological conviction—grounded in data and clear paths to translation that can become durable, scalable patient impact.

Accelerated insight with LABI

Our AI system speeds up how we analyze data, validate breakthroughs, and uncover real potential.

Hands-on industry leadership

We go beyond financial capital to work with founders that are innovating at the edge of innovative healthcare solutions.

Breakthrough science.
Disciplined execution.

We back teams translating breakthrough biology into therapies, diagnostics, and medical devices that can scale impact for patients.

Explore Portfolio

Research, analysis, and updates from our network

Articles, whitepapers, and expert commentary.

See More Insights
Whitepapers

Drug Development: The Alchemy of Hope

The journey from an idea to a commercialized medicine is, at its core, a human story.

See More
Podcasts
•External link

Delivering on the Promise of Precision Medicine: A Conversation with Dr. Allison Hulme of Aeovian Pharmaceuticals

Dr. Themasap Khan sits down with Aeovian Pharmaceuticals' President and CEO, Dr. Allison Hulme to discuss how she found herself in the pharma space, what's ahead for Aeovian, and why the work they are doing is so important for a population with an incredibly high unmet need.

See More
Whitepapers

From Blunt Sedation to Precise Disease Control: Insights into Anti-Seizure Medications

Living with epilepsy can feel like walking in a minefield: patients often feel like they need to tiptoe through their lives, fearful that any misstep or obscure catalyst can trigger a (potentially deadly) seizure. In the non-epileptic brain, neuron ensembles operate with one another in precise and synchronized coordination, giving rise to normal cognition, perception, and movement. In many epilepsy cases, patients develop seizures after an injury or other insult (e.g., traumatic brain injury, stroke, tumors, etc.) induces a structural malformation in the brain, serving as the source of abnormal discharges between neurons that manifest as seizures. In other cases, mutations in a variety of genes can disrupt the normal balance between excitation and inhibition within neurons, representing direct genetic causes of epilepsy.

See More